Abstract
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired, immune-mediated demyelinating neuropathy. It is the most common treatable acquired polyneuropathy and represents a significant number of initially undiagnosed neuropathy patients. This article reviews the common clinical, laboratory, and electrodiagnostic features of CIDP. In addition, current areas of uncertainty are discussed.
Similar content being viewed by others
References and Recommended Reading
Dyck PJ, Lais AC, Ohta M, et al.: Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975, 50:621–637.
Barohn RJ, Kissel JT, Warmolts JR, Mendell JR: Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 1989, 46:878–884.
Hattori N, Misu K, Koike H, et al.: Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2000, 184:57–63.
Gorson KC, Allam G, Ropper AH: Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997, 48:321–328.
Sabatelli M, Madia F, Mignogna T, et al.: Pure motor chronic inflammatory demyelinating polyneuropathy. J Neurol 2001, 248:772–777.
Prineas JW, McLeod JG: Chronic relapsing polyneuritis. J Neurol Sci 1976, 27:427–458.
Sakakibara R, Hattori T, Kuwabara S, et al.: Micturitional disturbance in patients with chronic inflammatory demyelinating polyneuropathy. Neurology 1998, 50:1179–1182.
van der Meche FG, van Doorn PA: Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: immune mechanisms and update on current therapies. Ann Neurol 1995, 37(suppl 1):S14-S31.
Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force: Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 1991, 41:617–618.
Dalakas M, Houff SA, Engel WK, Madden DL, Sever JL: CSF "monoclonal" bands in chronic relapsing polyneuropathy. Neurology 1980, 30:864–867.
Kissel JT, Mendell JR: Neuropathies associated with monoclonal proteins. Neuromusc Disord 1995, 6:3–18.
Albers JW, Kelly JJ: Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve 1989, 12:435–451.
Bromberg MB: Comparison of electrodiagnostic criteria for primary demyelination in chronic polyneuropathy. Muscle Nerve 1991, 14:968–976.
Rotta FT, Sussman AT, Bradley WG, et al.: The spectrum of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2000, 173:129–139.
Rhee EK, England JD, Sumner AJ: A computer simulation of conduction block: effects produced by actual block versus interphase cancellation. Ann Neurol 1990, 28:146–156.
Oh SJ, Kim DE, Koruoglu AR: What is the best diagnostic index of conduction block and temporal dispersion. Muscle Nerve 1994, 17:489–493.
Cornblath DR, Sumner AJ, Daube J, et al.: Conduction block in clinical practice. Muscle Nerve 1991, 14:869–871.
Olney RK: Consensus criteria for the diagnosis of partial conduction block. Muscle Nerve 1999, 22(suppl 8):S225-S229.
Molenaar DS, Vermeulen M, de Haan R: Diagnostic value of sural nerve biopsy in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 1998, 64:84–89.
Bosboom WM, Van den Berg LH, Franssen H, et al.: Diagnostic value of sural demyelination in chronic inflammatory demyelinating polyneuropathy. Brain 2001, 124:2427–2438.
Dyck PJ, O’Brien PC, Oviatt KF, et al.: Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982, 11:136–141.
Dyck PJ, Daube J, O’Brien P, et al.: Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986, 314:461–465.
Hahn AF, Bolton CF, Pillay N, et al.: Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: a double-blind, sham-controlled, cross-over study. Brain 1996, 119:1055–1066.
Hahn AF, Bolton CF, Zochodne D, Feasby TE: Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebocontrolled, cross-over study. Brain 1996, 119:1067–1077.
Mendell JR, Barohn RJ, Freimer ML, et al.: Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001, 56:445–449. In contrast to the chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) patients studied by Hahn et al. [24], the subjects of this trial had never been previously treated with any immunemodulating therapies. This study thus demonstrated that intravenous immunoglobulin can be an effective initial therapy for CIDP.
Hughes R, Bensa S, Willison H, et al.: Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001, 50:195–201.
Dyck PJ, O’Brien P, Swanson C, Low P, Daube J: Combined azathioprine and prednisone in chronic inflammatory demyelinating polyneuropathy. Neurology 1985, 35:1173–1176.
Barnett MH, Pollard JD, Davies L, McLeod JG: Cyclosporine A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 1998, 21:454–460.
Hodgkinson SJ, Pollard JD, McLeod JG: Cyclosporin A in the treatment of chronic demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 1990, 53:327–330.
Good JL, Chehrenama M, Mayer RF, Koski CL: Pulsed cyclophosphamide in chronic inflammatory demyelinating polyneuropathy. Neurology 1998, 51:1735–1738.
Brannagan TH, Pradham A, Heiman-Patterson T, et al.: High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology 2002, 58:1856–1858.
Sabatelli M, Mignogna T, Lippi G, et al.: Interferon-alpha may benefit steroid unresponsive chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 1995, 58:638–639.
Gorson KC, Ropper AH, Clark BD, et al.: Treatment of chronic inflammatory demyelinating polyneuropathy with interferon-alpha 2a. Neurology 1998, 50:84–87.
Mowzoon N, Sussman A, Bradley WG: Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci 2001, 185:119–122.
Chaudhry V, Cornblath DR, Griffin JW, O’Brien R, Drachman DB: Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001, 56:94–96.
Saperstein DS, Katz JS, Amato AA, Barohn RJ: Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001, 24:311–324.
Kyle RA, Dyck PJ: Neuropathy associated with the monoclonal gammopathies. In Peripheral Neuropathy, edn 3. Edited by Dyck PJ, Thomas PK, Griffin JW, Low PA, Podulso JF. Philadelphia: WB Saunders; 1993:1275–1287.
Katz JS, Saperstein DS, Gronseth GS, Amato AA, Barohn RJ: Distal acquired demyelinating symmetrical neuropathy. Neurology 2000, 54:615–620.
Simmons Z, Albers JW, Bromberg MB, Feldman EL: Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients without and with monoclonal gammopathy. Neurology 1993, 43:2202–2209.
Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G: Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 2000, 123:710–717.
Sharma KR, Cross J, Farronay O, et al.: Demyelinating neuropathy in diabetes mellitus. Arch Neurol 2002, 59:758–765.
Gorson KC, Ropper AH, Adelman LS, Weinberg DH: Influence of diabetes mellitus on chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2000, 23:37–43.
Sharma KR, Cross J, Ayyar DR, Martinez-Arizala A, Bradley WG: Diabetic demyelinating polyneuropathy responsive to intravenous immunoglobulin therapy. Arch Neurol 2002, 59:751–757.
Wilson JR, Park Y, Fisher MR: Electrodiagnostic criteria in CIDP: comparison with diabetic neuropathy. Electromyogr Clin Neurophysiol 2000, 40:181–185.
Barohn RJ, Sahenk Z, Warmolts JR, Mendell JR: The Bruns-Garland syndrome (diabetic amyotrophy). Revisited 100 years later. Arch Neurol 1991, 48:1130–1135.
Abu-Shakra SR, Cornblath DR, Avila OL, et al.: Conduction block in diabetic neuropathy. Muscle Nerve 1991, 14:858–862.
Tan E, Hajinazarian M, Bay W, Neff J, Mendell JR: Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol 1993, 50:137–139.
Nicolas G, Maisonobe T, Le Forestier N, Leger JM, Bouche P: Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2002, 25:26–30.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Saperstein, D.S., Barohn, R.J. Current concepts and controversy in chronic inflammatory demyelinating polyneuropathy. Curr Neurol Neurosci Rep 3, 57–63 (2003). https://doi.org/10.1007/s11910-003-0039-4
Issue Date:
DOI: https://doi.org/10.1007/s11910-003-0039-4